阜豐集團(00546.HK)侵權案獲判終極勝訴 被告須賠1,500萬人幣
阜豐集團(00546.HK)公布,就全資附屬公司山東阜豐發酵有限公司作為原告,就侵犯黃原膠生產商業秘密對新疆梅花、梅花生物及張偉提起的法律訴訟。
經過法院的多次審理,最高人民法院於1月9日作出終審判決,被告必須停止侵犯原告涉案黃原膠生產商業秘密的行為,包括不得披露、使用及允許他人使用涉案黃原膠生產商業秘密;及責令被告於法院終審判決之日起10日內賠償原告經濟損失1,500萬元人民幣。
最高人民法院的判決已經生效。原告正在考慮申請強制執行法院命令。原告正在尋求其中國法律顧問的法律意見,以採取適當的行動。董事會現時並不知悉訴訟及法院下令賠償將會對集團產生任何重大財務影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.